Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2018
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
- 29 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 1 Nov 2018.
- 21 Aug 2017 New trial record